Spero Therapeutics is a global multi-asset clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. Our mission is to become the leading player in the field of antibiotics. We aim to achieve this objective by rapidly advancing multiple, differentiated products towards commercialization in key territories.
SPR741, also called Potentiator, allows for a platform approach to combination therapy to treat serious and life-threatening multi-drug resistant Gram-negative infections, such as Enterobacteriaceae. SPR741 increases the spectrum and potency of more than two dozen classes of antibiotics to expand their activity against multidrug resistant Gram-negative infections when used in combination.SPR206, Spero’s next generation Potentiator molecule, is an IV direct-acting antibiotic that exhibits extremely high potency against multi-drug resistant pathogens that cause mortality, including Acinetobacter baumanii and Pseudomonas aeruginosa.